Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Jan. 27, 2025 — A study shows that patients with obesity and fatty liver-related cirrhosis who had bariatric (weight-loss) surgery significantly lowered their future ... Signposting Children to ...

Further pricing is expected to be the “primary” driver behind the chocolate and snacks maker’s 2% revenue growth outlook for ...

Novo Nordisk A/S NVO reported fourth-quarter 2024 earnings of 91 cents per American Depositary Receipt (ADR), which beat the ...

We break down the history behind BMI and how body fat percentage relates to your health. Read more to get a better ...

The Trump administration has pledged to slash government spending while promising to “make America healthy again ... including liver disease, obesity, high blood pressure and other ...

Instituto Nacional de Salud Pública, Av. Universidad No. 655. Col. Sta. Ma. Ahuacatitlan, Cuernavaca, Morelos, CP. 62100, Mexico Among the main drivers causing this shift in obesity prevalence is a ...

This summer, our beleaguered big screens will welcome the return of America’s most famous illegal alien: Superman. This much needed reboot comes as President Trump, who earned my vocal support ...

The companies Immunovant, Verdiva Bio, and Akero Therapeutics bagged the biggest biotech funding rounds overall in January ...

Last Patient / Last Visit Completed Topline Data Readout Expected Later This Quarter CRANBURY, N.J., Feb. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc.

Novo Nordisk's recent decline suggests it may be a Buy again, with strong growth prospects in diabetes and obesity treatments ...